AtriCure (ATRC) risk factors, FY2025 10-K

Other

1. 01Competition from existing and new products and procedures may decrease our market share and may cause our revenue to decline, and could adversely affect our operating results
2. 02Any clinical data that is generated regarding our products may not be positive, and our current and planned clinical trials may not satisfy the requirements of the FDA or other regulatory authorities
3. 03We rely on independent distributors to market and sell our products in certain markets outside of the United States, and a failure of our independent distributors to successfully market our products or any disruption in their ability to do so may adversely impact our sales

Industry Conditions Risks

1. 04A prolonged downturn in macroeconomic conditions may materially and adversely affect our business
2. 05Healthcare costs have risen significantly over the past decade. There have been and may continue to be proposals by legislators, regulators and third-party payors to contain or reduce healthcare costs
3. 06Adverse changes in governmental and third-party payors’ policies toward coverage and reimbursement for surgical procedures would harm our ability to promote and sell our products

Operational Risks

1. 07We may experience unfavorable publicity relating to our business or our industry. This publicity could have a negative impact on our sales, our ability to attract and retain customers, clinical studies involving our products, our reputation and our stock price
2. 08We rely upon single and limited source third-party suppliers and third-party service providers, making us vulnerable to supply problems and price fluctuations which could harm our business
3. 09Our manufacturing operations are highly centralized, and disruption at our manufacturing facilities could increase our expenses and decrease our revenue
4. 10If we fail to properly manage our anticipated growth, our business could suffer57% rewritten
5. 11We depend on our officers and other skilled and experienced personnel to operate our business effectively. If we are not able to retain our current employees or recruit, hire, train and integrate additional qualified personnel, our business will suffer and our future revenue and profitability will be impaired
6. 12Disruptions of critical information systems or material breaches in the security of our systems could harm our business, customer relations and financial condition
7. 13Our insurance may not cover our indemnification obligations and other liabilities associated with our operations

Legal & Compliance Risks

1. 14We spend considerable time and money complying with federal, state and foreign regulations in addition to FDA regulations, and, if we do not fully comply with such regulations, we could face substantial penalties
2. 15If we fail to comply with the extensive FDA regulations relating to our business, we may be subject to fines, injunctions and penalties, and our ability to commercially distribute and promote our products may be hurt
3. 16If any of these events were to occur, we could lose customers and our production, product sales, business, results of operations and financial condition would be harmed
4. 17Modifications to our products may require new clearances or approvals or may require us to cease promoting or to recall the modified products until such clearances or approvals are obtained and FDA may not agree with our conclusions regarding whether new clearances or approvals were required
5. 18If we or our third-party vendors fail to comply with extensive FDA regulations relating to the manufacturing of our products or component parts, we may be subject to fines, injunctions and penalties, and our ability to commercially distribute and sell our products may be hurt
6. 19The use of products we sell may result in injuries or other adverse events that lead to product liability suits, which could be costly to our business or our customers’ businesses
7. 20Our intellectual property rights may not provide meaningful commercial protection for our products, which could enable third parties to use our technology or methods, or very similar technology or methods, and could reduce our ability to compete88% rewritten
8. 21patents and those that may be issued in the future may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related productsNew
9. 22We sell our products outside of the United States, and we are subject to various regulatory and other risks relating to international operations, which could harm our revenue and profitability
10. 23Changes in United States and international trade policies may adversely impact our business and operating resultsNew
11. 24Due to the global nature of our business, we may be exposed to liabilities under the Foreign Corrupt Practices Act and various other anti-corruption laws, and any allegation or determination that we violated these laws could have a material adverse effect on our business
12. 25The use of artificial intelligence ("AI") technology by our employees or business partners could result in misuse or loss of proprietary information, violation of laws and regulations, or damage to our reputation and credibility

Financial Risks

1. 26Our quarterly financial results are likely to fluctuate significantly because the pace of adoption of our products by clinicians is uncertain
2. 27We have a history of net losses, including $11,448 in 2025, $44,698 in 2024, and $30,438 in 2023. As of December 31, 2025, we had an accumulated deficit of $413,20322% rewritten
3. 28Governmental authorities may challenge our intercompany transfer pricing policies or change their laws in a manner that could increase our effective tax rate or otherwise harm our business
4. 29If our goodwill becomes impaired, it could materially reduce the value of our assets and reduce our net income or increase our net loss for the year in which the impairment occurs
5. 30An inability to forecast future revenue or estimate life cycles of products may result in inventory-related charges that would negatively affect our gross margins and results of operations
6. 31We are subject to credit risk from our accounts receivable related to our sales, which include sales into countries outside the United States that may experience economic turmoil
7. 32We may be unable to comply with the covenants of our Credit Agreement23% rewritten

Common Stock Risks

1. 33We may fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could cause a decline in our stock price
2. 34Securities analysts may not continue, or additional securities analysts may not initiate, coverage for our common stock or may issue negative reports. This may have a negative impact on the market price of our common stock
3. 35The price and trading volume of our common stock may experience extreme fluctuations and our stockholders could lose some or all of their investment
4. 36The sale of material amounts of common stock could encourage short sales by third parties and depress the price of our common stock. As a result, our stockholders may lose all or part of their investment
5. 37Sales of common stock by us in a capital raising transaction or our issuances of shares in an acquisition may dilute stockholder ownership of common stock and cause a decline in the market price of our common stock
6. 38Anti-takeover provisions in our amended and restated certificate of incorporation and amended and restated bylaws and under Delaware law could inhibit a change in control or a change in management that stockholders consider favorable
7. 39We do not expect to pay dividends in the foreseeable future. As a result, stockholders must rely on stock appreciation for any return on investment